Revolution Medicines, Inc. Stock Price, News & Analysis

Revolution Medicines (Nasdaq: RVMD) announced the closing of a public offering of 6,900,000 shares at $26.00 each, generating gross proceeds of $179.4 million before deductions. The offering included 900,000 additional shares purchased by underwriters. The funds are expected to support the company’s focus on developing targeted cancer therapies, specifically those targeting RAS and mTOR pathways. J.P. Morgan, Cowen, SVB Leerink, and Guggenheim Securities managed the offering.

Revolution Medicines has announced a public offering of 6,000,000 shares of common stock at a price of $26.00 per share, aiming to raise approximately $156 million before expenses. The offering includes an option for underwriters to purchase up to 900,000 additional shares. The offering is set to close on July 13, 2020, subject to standard closing conditions. Notable financial institutions involved include J.P. Morgan, Cowen, SVB Leerink, and Guggenheim Securities.

Revolution Medicines, Inc. (Nasdaq: RVMD) has launched an underwritten public offering of 5,500,000 shares of common stock. The company plans to grant underwriters a 30-day option to purchase an additional 825,000 shares. J.P. Morgan, Cowen, SVB Leerink, and Guggenheim Securities are serving as joint book-running managers for the offering. A registration statement has been filed with the SEC, but it is not yet effective. This press release does not constitute an offer to sell or a solicitation to buy securities.

Revolution Medicines, Inc. (Nasdaq: RVMD) announced the publication of research in the Proceedings of the National Academy of Sciences detailing a compound, WDB002, that inhibits the CEP250 protein, which may also target SARS-CoV-2. This discovery could lead to new antiviral candidates. The company has licensed the intellectual property to Ginkgo Bioworks for further development against infectious diseases. Revolution Medicines remains focused on oncology therapies while exploring the antiviral potential of WDB002, collaborating with Ginkgo to expedite research efforts in the face of COVID-19.

Revolution Medicines (Nasdaq: RVMD) provided a comprehensive R&D update on June 22, 2020, focusing on advancements in their RMC-4630 clinical program aimed at treating RAS cancers. Key highlights include improved pharmacokinetics and tolerability from intermittent dosing, anti-tumor activity data in non-small cell lung cancer patients with KRAS mutations, and promising results from novel dual-target therapies in preclinical models. The company continues to expand its innovative pipeline, emphasizing targeted therapies within the RAS and mTOR pathways.

Revolution Medicines (Nasdaq: RVMD) announced the dosing of the first patient in a multicenter Phase 1 clinical trial for RMC-4630 (SAR442720), a SHP2 inhibitor, in combination with pembrolizumab (Keytruda). This trial targets patients with advanced malignancies like non-small cell lung cancer and colorectal cancer. The study aims to evaluate safety and preliminary efficacy. Previous research suggests that RMC-4630 may enhance anti-tumor effects when used with immune checkpoint inhibitors. The company aims to explore broader applications of RMC-4630 in RAS-dependent tumors.

Revolution Medicines, Inc. (Nasdaq: RVMD) has appointed Eric T. Schmidt, Ph.D., and Peter Svennilson to its board of directors. Schmidt, previously CFO at Allogene Therapeutics, brings extensive biotechnology experience from Wall Street, while Svennilson has over 35 years in venture capital and finance. Their appointments aim to enhance the company's financial expertise as it matures. This follows the resignation of Larry Lasky, Ph.D., who will remain a scientific advisor. Revolution Medicines focuses on targeted therapies for cancer, with a robust pipeline including RMC-4630 and other key oncology targets.

Revolution Medicines (Nasdaq: RVMD) has initiated dosing in a Phase 1b clinical trial for its investigational SHP2 inhibitor, RMC-4630, combined with Amgen's KRAS^G12C inhibitor, AMG 510. The trial targets advanced solid tumors with the KRAS^G12C mutation, focusing on safety, tolerability, and efficacy. RMC-4630 aims to overcome resistance in RAS-dependent tumors and is part of a broader therapeutic strategy involving multiple combination treatments. This trial marks a significant step in Revolution Medicines' efforts to advance cancer therapies targeting the RAS pathway.